Despite the high expression of VEGF in breast tumors and its adverse impact on the clinicopathologic features, angiogenesis inhibitors targeting VEGF and/or its receptors have consistently failed to produce favorable treatment outcomes in breast cancer [4]. This evidence concerns the gene VEGFA and breast carcinoma.